Co-Diagnostics Inc
NASDAQ:CODX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.01
1.75
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Co-Diagnostics Inc
Current Portion of Long-Term Debt
Co-Diagnostics Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Co-Diagnostics Inc
NASDAQ:CODX
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Becton Dickinson and Co
NYSE:BDX
|
Current Portion of Long-Term Debt
$2.2B
|
CAGR 3-Years
63%
|
CAGR 5-Years
11%
|
CAGR 10-Years
27%
|
||
Boston Scientific Corp
NYSE:BSX
|
Current Portion of Long-Term Debt
$1.7B
|
CAGR 3-Years
85%
|
CAGR 5-Years
5%
|
CAGR 10-Years
88%
|
||
Stryker Corp
NYSE:SYK
|
Current Portion of Long-Term Debt
$2.2B
|
CAGR 3-Years
361%
|
CAGR 5-Years
33%
|
CAGR 10-Years
11%
|
||
Abbott Laboratories
NYSE:ABT
|
Current Portion of Long-Term Debt
$1.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
5%
|
CAGR 10-Years
23%
|
||
Intuitive Surgical Inc
NASDAQ:ISRG
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Co-Diagnostics Inc
Glance View
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.